Impact of race and ethnicity on financial toxicity in patients with genitourinary cancers.
Atulya Aman Khosla(Baptist Hospital of Miami), Ulka N. Vaishampayan(University of Michigan), Mohammad Arfat Ganiyani(Baptist Hospital of Miami), Mukesh Roy(Baptist Health South Florida), Muni Rubens(Florida International University), Anshul Saxena(Florida International University), Rohan Garje(Baptist Hospital of Miami), Ishmael Jaiyesimi(Beaumont Hospital, Royal Oak), Shreyas Bellur(Baptist Hospital of Miami), Rohit Singh(University of Vermont Medical Center), Karan Jatwani(Roswell Park Comprehensive Cancer Center), Nitya Batra(Jacksonville College), Ahmad Ozair(King George's Medical University)
Cited by 0
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Intermittent versus Continuous Androgen Deprivation in Prostate Cancer
|New England Journal of Medicine|2013|568
Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
|Journal of Clinical Oncology|2019|147
Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|125
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline
|Journal of Clinical Oncology|2022|116